NewcelX Ltd. has announced that Professor Tamir Ben-Hur, a leading neurologist and expert in neuroimmunology and stem-cell-based regenerative medicine, will join its Scientific Advisory Board. This development follows the unification of Kadimastem Ltd.'s advanced stem-cell platforms and clinical programs with NLS Pharmaceutics Ltd.'s expertise in central nervous system therapeutics, forming the foundation of NewcelX. The company aims to advance transformative cell therapies for neurodegenerative and metabolic diseases, including ALS and diabetes. Professor Ben-Hur's appointment is seen as a strong endorsement of the combined scientific vision and clinical ambitions of the new entity.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO17614) on November 06, 2025, and is solely responsible for the information contained therein.